Logo image of ELEV

ELEVATION ONCOLOGY INC (ELEV) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ELEV - US28623U1016 - Common Stock

0.365 USD
-0.01 (-2.12%)
Last: 7/22/2025, 8:03:19 PM
0.377 USD
+0.01 (+3.29%)
After Hours: 7/22/2025, 8:03:19 PM
Fundamental Rating

2

Taking everything into account, ELEV scores 2 out of 10 in our fundamental rating. ELEV was compared to 530 industry peers in the Biotechnology industry. The financial health of ELEV is average, but there are quite some concerns on its profitability. ELEV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ELEV has reported negative net income.
In the past year ELEV has reported a negative cash flow from operations.
In the past 5 years ELEV always reported negative net income.
ELEV had a negative operating cash flow in each of the past 5 years.
ELEV Yearly Net Income VS EBIT VS OCF VS FCFELEV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ELEV has a Return On Assets of -58.36%. This is comparable to the rest of the industry: ELEV outperforms 42.68% of its industry peers.
ELEV has a Return On Equity of -102.69%. This is comparable to the rest of the industry: ELEV outperforms 44.85% of its industry peers.
Industry RankSector Rank
ROA -58.36%
ROE -102.69%
ROIC N/A
ROA(3y)-66.25%
ROA(5y)-48.31%
ROE(3y)-117.18%
ROE(5y)-79.52%
ROIC(3y)N/A
ROIC(5y)N/A
ELEV Yearly ROA, ROE, ROICELEV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

ELEV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ELEV Yearly Profit, Operating, Gross MarginsELEV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for ELEV has been increased compared to 1 year ago.
ELEV has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ELEV has been reduced compared to a year ago.
ELEV Yearly Shares OutstandingELEV Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ELEV Yearly Total Debt VS Total AssetsELEV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -4.67, we must say that ELEV is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ELEV (-4.67) is comparable to the rest of the industry.
ELEV has a Debt/Equity ratio of 0.67. This is a neutral value indicating ELEV is somewhat dependend on debt financing.
The Debt to Equity ratio of ELEV (0.67) is worse than 75.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF N/A
Altman-Z -4.67
ROIC/WACCN/A
WACCN/A
ELEV Yearly LT Debt VS Equity VS FCFELEV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 19.40 indicates that ELEV has no problem at all paying its short term obligations.
ELEV's Current ratio of 19.40 is amongst the best of the industry. ELEV outperforms 92.77% of its industry peers.
ELEV has a Quick Ratio of 19.40. This indicates that ELEV is financially healthy and has no problem in meeting its short term obligations.
ELEV has a Quick ratio of 19.40. This is amongst the best in the industry. ELEV outperforms 92.77% of its industry peers.
Industry RankSector Rank
Current Ratio 19.4
Quick Ratio 19.4
ELEV Yearly Current Assets VS Current LiabilitesELEV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

ELEV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.15%, which is quite impressive.
EPS 1Y (TTM)21.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 16.56% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.71%
EPS Next 2Y14.77%
EPS Next 3Y12.42%
EPS Next 5Y16.56%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ELEV Yearly Revenue VS EstimatesELEV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2031 2032 20M 40M 60M 80M 100M
ELEV Yearly EPS VS EstimatesELEV Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ELEV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ELEV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ELEV Price Earnings VS Forward Price EarningsELEV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ELEV Per share dataELEV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ELEV's earnings are expected to grow with 12.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.77%
EPS Next 3Y12.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ELEV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ELEVATION ONCOLOGY INC

NASDAQ:ELEV (7/22/2025, 8:03:19 PM)

After market: 0.377 +0.01 (+3.29%)

0.365

-0.01 (-2.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners47.19%
Inst Owner Change-99.41%
Ins Owners0.35%
Ins Owner Change-0.38%
Market Cap21.63M
Revenue(TTM)N/A
Net Income(TTM)-47.99M
Analysts72.86
Price Target1.52 (316.44%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.58%
Min EPS beat(2)-22.07%
Max EPS beat(2)20.91%
EPS beat(4)2
Avg EPS beat(4)2.87%
Min EPS beat(4)-22.07%
Max EPS beat(4)21.12%
EPS beat(8)4
Avg EPS beat(8)4.02%
EPS beat(12)4
Avg EPS beat(12)-1.93%
EPS beat(16)5
Avg EPS beat(16)-8.7%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-27.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-29.48%
EPS NY rev (1m)0.44%
EPS NY rev (3m)-10.92%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.46
P/tB 0.46
EV/EBITDA N/A
EPS(TTM)-0.82
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS0.79
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -58.36%
ROE -102.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.25%
ROA(5y)-48.31%
ROE(3y)-117.18%
ROE(5y)-79.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.67
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.4
Quick Ratio 19.4
Altman-Z -4.67
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4.35%
EPS Next Y7.71%
EPS Next 2Y14.77%
EPS Next 3Y12.42%
EPS Next 5Y16.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.26%
OCF growth 3YN/A
OCF growth 5YN/A

ELEVATION ONCOLOGY INC / ELEV FAQ

Can you provide the ChartMill fundamental rating for ELEVATION ONCOLOGY INC?

ChartMill assigns a fundamental rating of 2 / 10 to ELEV.


Can you provide the valuation status for ELEVATION ONCOLOGY INC?

ChartMill assigns a valuation rating of 0 / 10 to ELEVATION ONCOLOGY INC (ELEV). This can be considered as Overvalued.


What is the profitability of ELEV stock?

ELEVATION ONCOLOGY INC (ELEV) has a profitability rating of 1 / 10.


Can you provide the financial health for ELEV stock?

The financial health rating of ELEVATION ONCOLOGY INC (ELEV) is 4 / 10.


What is the earnings growth outlook for ELEVATION ONCOLOGY INC?

The Earnings per Share (EPS) of ELEVATION ONCOLOGY INC (ELEV) is expected to grow by 7.71% in the next year.